Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Aneurysmal Subarachnoid Hemorrhage
NCT06648187, Not applicable, Completed, National Taiwan University Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Aneurysmal Subarachnoid Hemorrhage | ClinicalTrials.gov |
| NCT number | NCT06648187 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 6 participants, actual | ClinicalTrials.gov |
| Lead sponsor | National Taiwan University Hospital | ClinicalTrials.gov |
| Conditions | Subarachnoid Aneurysm Hemorrhage | ClinicalTrials.gov |
| Interventions | Early motor-cognitive integrative training (e-MCIT) | ClinicalTrials.gov |
| First posted | 2024-10-18 | ClinicalTrials.gov |
| Last updated | 2026-05-11 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Global cognition | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Global cognitive function will be measured by Montreal Cognitive Assessment (MoCA). Sum of score ranges from 0 to 30. There are eight subdivision of cognition category in this test, including visuospatial/ executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Many studies assess global cognitive function in SAH patient by MoCA, which showed less ceiling or floor effect. | ClinicalTrials.gov |
| Primary | Executive function | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Executive function will be measured by three tests: Trail Making Test part A(TMT-A), Trail Making Test part B(TMT-B) and Stroop color and word test (SCWT), and scoring is based on time taken to complete the test with lower scores being better. Accuracy rate will be recorded as well. | ClinicalTrials.gov |
| Primary | Working memory | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Working memory will be measured by digit span (DS) test, which also usually represents subject's ability of verbal memory. Indicator for DS is the sum of the total scores for forward and reverse DS, with a score range of 0-30 points. A higher score indicates better performance. | ClinicalTrials.gov |
| Primary | Attention | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Attention ability will be measure by Go and no-go (GNG) test, which also represents subject's ability of set shifting, processing speed, and selective inhibition or also called inhibitory control. | ClinicalTrials.gov |
| Primary | Language ability | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | In category of language ability, verbal fluency will be measured by Semantic Verbal Fluency test (SVFT). The session consisted of three trials. Trials consisted of three different characters with the same pronunciation (20s / a Chinese character). The stimulation task was randomized to every subjects. Between three trails, there are 30 seconds in resting periods. Score 1 point for each correct answer, with total score of nine. Every correct and incorrect instance will be recorded. Accuracy rate (AR) will be calculated as the same method in GNG test. A higher accuracy rate also indicates better performance. | ClinicalTrials.gov |
| Secondary | Brain activity | T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Functional Near-Infrared Spectroscopy (fNIRS), which is a non-invasive neuro-imaging technique, will be used to detect the cerebral hemodynamics. The fNIRS data acquire via multichannel wearable fNIRS imaging system (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NYC, USA). Exports and receives dual-wavelength near-infrared signals are 760 and 850 nm. Data collection includes measurement changes in oxyhemoglobin \[HbO\], de-oxyhemoglobin \[HbR\] and the difference between HbO and HbR. The probe will not be placed above the surgical wound site. In cognition assessments: TMT-A\& TMT-B, SCWT, DS, and GNG test, Optodes are configured to target both the bilateral prefrontal cortex (PFC) and the posterior parietal cortex (PPC). The setup involves 16 LED light sources and 16 detectors (16x16), resulting in 39 channels for the collection of hemodynamic data. | ClinicalTrials.gov |
| Secondary | Motor impairment | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Motor impairment after stroke was measured by Fugl-Meyer Assessment for upper extremity (FMA-UE) and lower extremity (FMA-LE). In FMA-UE, part A to D, including subtests of upper extremity, wrist, hand, and coordination/ speed will be used only. The score ranges from 0 to 66. In FMA-LE, part E to F, including subtests of lower extremity, and coordination/ speed will be used only. The score ranges from 0 to 34. Both scores with higher score indicates better motor function | ClinicalTrials.gov |
| Secondary | Muscle strength | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Key muscles strength was measured by Medical Research Council (MRC) scale. The scoring system is the same with manual muscle testing (MMT), with grade from 0 to 5. Total of score is 60, with higher scores indicating better strength. | ClinicalTrials.gov |
| Secondary | Ability of ambulation | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Functional ambulatory category (FAC) would be used to assess the subject's ability of ambulation. FAC consists of six level, ranging from 0 to 5. The higher level indicates better ability of ambulation. | ClinicalTrials.gov |
| Secondary | Functional Independence in ADL | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Functional independence measure (FIM) would be used to evaluate subject's ability of ADL. FIM consists of motor items and cognitive items. Motor items include subtest of self-care, sphincter control, mobility/ transfer, and locomotion. Cognitive items include subtest of communication and social cognition. The higher score indicates better independent ability. Scoring levels range from 1 to 7, thus, sum of score in FIM ranges from 18 to 126. The higher score indicates better independent ability. | ClinicalTrials.gov |
| Secondary | Functional ability | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks), T2(discharge from hospital, an average of 4weeks) | Modified Rankin Scale (mRS) would be used to assess the degree of disability or dependence in ADL. There are seven levels in mRS, with ranging from 0 to 6. Among this scale, the higher scale indicates less function ability. | ClinicalTrials.gov |
| Secondary | Functional status in ICU | All tested at T0(baseline), T1(discharge from ICU, an average of 2 weeks) | Perme ICU mobility score will be assessed at first time evaluation in ICU and discharge from ICU, which including mental status, potential mobility barriers, functional strength and functional ability. The higher score indicates better function status. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 5
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)